The QualityStocks Daily Tuesday, April 21st, 2020

Today's Top 3 Investment Newsletters

MarketClub Analysis (NNVC) +33.62%

TradersPro (VXRT) +33.33%

SmallCapRelations (ISGI) +30.00%

The QualityStocks Daily Stock List

American BriVision (Holding) Corporation (ABVC)

InvestorPoint, AA Stocks, TipRanks, Market Screener, Morningstar, Drug Discovery Online, TradingView, Stockopedia, Real Investment Advice, Internet Stock Review, TMXmoney, Wallet Investor, Corporate Information, 4-Traders, Stockhouse, GlobeNewswire, Stockwatch, Financial Content, Simply Wall St, Nasdaq, and Street Insider reported earlier on American BriVision corporation (ABVC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

American BriVision (Holding) Corporation is a clinical stage biopharmaceutical company headquartered in Fremont, California. It is developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology. The Company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. Established in 2015, American BriVision lists on the OTC Markets Group’s OTCQB.

American BriVision focuses on using its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions. These include Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. The Company then focuses on out-licensing the products to international pharmaceutical companies for pivotal Phase III studies and, eventually, generating global sales.

In June of 2019, American BriVision released positive clinical results showing efficacy and safety for its ABV-1504 Phase II (Part 2) trial, under the U.S. Food and Drug Administration (FDA) and Taiwan FDA clinical protocol code of BLI-1005-002, in major depressive disorder (MDD). The study was a randomized, double-blind, placebo-controlled, multi-center trial. Sixty adult patients with confirmed moderate-to-severe MDD were treated with PDC-1421 low dose (380 mg), PDC-1421 high dose (2 x 380 mg), or placebo for 6 weeks, three times per day. PDC-1421 is the active pharmaceutical ingredient of ABV-1504.

PDC-1421 high dose (2 x 380 mg) met the prespecified primary endpoint by demonstrating a highly significant 13.2-point reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score by Intention-To-Treat (ITT) analysis, averaged over the 6-week treatment period from baseline ( overall treatment effect), versus a 9.2-point reduction in the placebo group. The results support further development of PDC-1421 in MDD. The low and high doses of PDC-1421 were safe and well tolerated with no serious adverse events.

American BriVision announced this past October encouraging results from the First-in-Human Clinical Trial (feasibility study or study) for Vitargus®, its investigational medical device. Feasibility Study results suggest Vitargus® is safe and well-tolerated and may be a viable vitreous substitute to be used in vitrectomy surgeries. Assuming sufficient funding, American BriVision will initiate a multi-national, multi-site pivotal study for Vitargus® in 2020.

In November 2019, American BriVision issued a full clinical study report (CSR), under the U.S. Food and Drug Administration (FDA) and Taiwan FDA (TFDA) clinical protocol code of BLI-1005-002, for ABV-1504 major depressive disorder (MDD) Phase II study. PDC-1421 high-dose data met the primary endpoint on MADRS scale in ITT clinical trial population. PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no serious adverse events associated with them in the Phase II clinical trial.

Last month, American BriVision announced the first patient enrollment of ABV-1505 Phase II Part I clinical trial, under the U.S. Food and Drug Administration (FDA) clinical protocol code BLI-1008-001, for adult attention-deficit hyperactivity disorder (ADHD). The new study will be conducted at the University of California San Francisco (UCSF) Medical Center.

Earlier this month, American BriVision announced that a site monitoring visit was conducted on March 10 and March 11, 2020 at the University of California San Francisco (UCSF) Medical Center for ABV-1505 Phase II Part I clinical trial, under the FDA clinical protocol code BLI-1008-001, for Adult Attention-Deficit Hyperactivity Disorder (ADHD). The trial is an open label, single-center and dose escalation study designed for the enrollment of six adult ADHD patients. Each patient will receive a low-dose treatment (380 mg) of PDC-1421 Capsules three times daily for 28 days followed by a high-dose treatment (760 mg) three times daily for another 28 days.

American BriVision corporation (ABVC), closed Tuesday's trading session at $3.20, up 10.3448%, on 700 volume with 3 trades. The average volume for the last 3 months is 1,466 and the stock's 52-week low/high is $1.04999995/$21.50.

American International Holdings Corp. (AMIH)

Wolf Street, Street Insider, Stocks to Buy, Stockhouse, Wallet Investor, Last10k, Research Pool, Seeking Alpha, Market Screener, TipRanks, GuruFocus, Nasdaq, OTC Markets, Investors Hub, Trading View, MarketWatch, Stockopedia, Equities.com, Simply Wall St, Dividend Investor, Current Charts, and GlobeNewswire reported earlier on American International Holdings Corp. (AMIH), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

American International Holdings Corp. is a diversified holding company listed on the OTC Markets. Its commitment is to acquiring, managing and operating health, wellness, beauty, and lifestyle companies, businesses and/or brands located in the United States and internationally. The Company looks for opportunities to acquire and grow businesses that have strong brand values and that can produce long-term sustainable free cash flow and attractive returns to maximize value for American International and its stakeholders. Incorporated on August 18, 1986, American International Holdings is headquartered in Houston, Texas.

American International has its subsidiary, YS Brands, Inc. YS Brands was created as a wholly-owned subsidiary. Its commitment is to creating, designing, manufacturing and marketing new premium designer shoe concepts intended to sell through direct to consumer (retail and e-commerce) and wholesale via larger, bigger box retail stores.

In addition, American International owns and operates a medical spa under the Novopelle brand name in McKinney, Texas. The Company announced in October of 2019 that it appointed Mr. JJ Dickens as the Chief Executive Officer (CEO) of its newly formed wholly-owned subsidiary, Capitol City Solutions USA, Inc. (CCS). CCS was formed to act as a general contracting and construction company centered on the remodeling, general construction and interior finish of the Company’s newly created Novopelle branded med spa locations as well as to market to other commercial real estate projects within the U.S. Mr. Dickens brings greater than 10 years of construction and project management experience to CCS.

American International Holdings’ wholly-owned subsidiary, Novopelle Waterway, Inc. officially opened the doors to its Novopelle Med Spa located at the award-winning Woodlands Waterway in The Woodlands, Texas, on Tuesday, February 25th, 2020. Novopelle Waterway executed a 1,254 square-foot retail lease agreement on November 6, 2019 with the Howard Hughes Corporation. This marks the second Novopelle Med Spa location to be established and operated by the Company.

Last month, American International Holdings announced that it entered into a non-binding Letter of Intent (LOI) to acquire all of the assets associated with and related to a retail vitamin, supplements and nutrition store now identified and doing business as “Shredded Supplements” in Plano, Texas. Upon the closing of the transaction, which is subject to customary closing conditions and the mutual agreement of a definitive asset purchase agreement, American International intends to immediately rebrand this location to act as its second Legend Nutrition branded supplement store in its portfolio.

American International Holdings Corp. (AMIH), closed Tuesday's trading session at $0.17, even for the day, on 14,943 volume with 6 trades. The average volume for the last 3 months is 22,780 and the stock's 52-week low/high is $0.134000003/$2.40000009.

n

American Shipping Company ASA (ASCJF)

OTC Markets, Talk Markets, Penny Stock Hub, YCharts, GlobeNewswire, Dividend Investor, Morningstar, Stockhouse, Nasdaq, Dividend.com, GuruFocus, Business Wire, Wallet Investor, 4-Traders, Market Screener, TradingView, Barchart, OTC.Watch, MarketWatch, Seeking Alpha, PR Newswire and Proactive Investors reported beforehand on American Shipping Company ASA (ASCJF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

American Shipping Company ASA (AMSC) is a ship owning company headquartered in Lysaker, Norway. The Company’s U.S. office is in Kennett Square, Pennsylvania. AMSC is a ship finance enterprise focused on the intercoastal U.S. Jones Act shipping market. It charters its vessels on long term bareboat charters that provide stable, predictable cash flow. Established in 2005, AMSC’s shares trade on the OTC Markets Group’s OTCQX.

The Company owns a fleet of nine modern handy size product tankers and one modern handy size shuttle tanker on long term bareboat charter with Overseas Shipholding Group (OSG). OSG charters the vessels out on time charters to major oil companies in the U.S. coastwise Jones Act trade. AMSC has a considerable contract backlog and also a profit sharing agreement with OSG that offers visibility regarding future earnings and potential dividend capacity.

The U.S. Jones Act requires that waterborne transportation of merchandise between two points in the USA must take place aboard a vessel that is U.S.-built, U.S.-owned, U.S.-flagged, and U.S.-crewed. This is also known as coastwise trade; it is governed by cabotage laws.

Aker ASA is the largest shareholder of AMSC with approximately 19 percent of the shares. AMSC has four bareboat contracts expiring in 2020; five bareboat contracts expiring in 2022; and a shuttle tanker bareboat contract expiring in June of 2025. The Company fleet caters the crude oil and refined petroleum products logistics for oil majors and refiners in the U.S. coastal trade. AMSC’s emphasis is on building a first-rate ownership position in the Jones Act market to create maximum value for its shareholders.

In December of 2019, Overseas Shipholding Group, Inc. (OSG) and AMSC jointly announced that OSG exercised options to extend its bareboat charter agreements with AMSC for four vessels presently under charter from AMSC. Each bareboat charter agreement was extended for additional three-year terms, starting from December 2020 and ending in December 2023. OSG earlier exercised its options to extend charter agreements for all of the six other vessels that it leases from AMSC. Therefore, all ten bareboat charter agreements with AMSC have now been extended for additional periods.

American Shipping Company ASA (ASCJF), closed Tuesday's trading session at $2.28, even for the day, on 55 volume with 1 trade. The average volume for the last 3 months is 2,658 and the stock's 52-week low/high is $1.39849996/$4.26000022.

AMMO, Inc. (POWW)

Macroaxis, SavvyTrader Resource, OTC Dynamics, last10k, Financial Buzz, Infront Analytics, TipRanks, YCharts, Barchart, The Street, Stockopedia, Wallmine, Dividend Investor, Stockhouse, 4-Traders, InvestorsHub, Simply Wall St, Seeking Alpha, GlobeNewswire, GuruFocus, Morningstar, Wallet Investor, Stockwatch, Dividend.com, Investors Hangout, Business Insider, Market Screener, Trading View and MarketWatch reported beforehand on AMMO, Inc. (POWW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AMMO, Inc. is a technology leader and premier American ammunitions manufacturer. The Company designs and manufactures products for a variety of aptitudes. These include law enforcement, military, hunting, sport shooting, and self-defence. The Company operates a munitions manufacturing facility in Payson, Arizona, and a brass casings manufacturing facility in Manitowoc, Wisconsin. Established in 2016, AMMO is based in Scottsdale, Arizona and lists on the OTC Markets’ OTCQB.

AMMO promotes branded munitions. These include its patented STREAK™ Visual Ammunition, the Jesse James line of munitions and accessories, /stelTH/ subsonic munitions, O.W.L. Technologies®, TAC-PTM Tactical Precision Defense munitions, and OPS (One Precise Shot). OPS is a lead-free frangible tactical line of munitions for self-defence.

The ammunition AMMO builds performs like high end custom hand loaded ammunition. The Company works to be the leading innovator of center-fire ammunition for military, law enforcement, and civilians. Every load is developed for a specific purpose. The focus is on consistency, accuracy, and, in some cases, felt recoil. Each round is designed, manufactured, inspected and packaged to bring a first-rate shooting experience to AMMO’s end consumer. In addition, the Company’s HyperClean technology enables its customers to shoot more and clean less.

AMMO launched in 2019 its patented Hard Armor Piercing Incendiary (HAPI) and Armor Piercing (AP) ammunition manufacturing line. It is presently manufacturing best-in-class 308 (7.62x51mm) and .338 ammunition in HAPI and AP variants for use by its U.S. and overseas military and law enforcement partners. AMMO’s work in industrializing the manufacturing of its AP and HAPI ammunition was specifically deployed to serve the increasing international military and law enforcement ammunition market.

Last week, AMMO announced the rollout of its complete portfolio of loaded ammunition, including its STREAK™ Visual Ammunition, brass casings and munition components, to an additional 201 retail stores in the first 15 days of the quarter across the United States. Included in the rollout were 150 Rural King and Murdoch’s Ranch & Home Supply locations.

Today, AMMO provided selected preliminary unaudited results for its Q4 and fiscal year ended March 31, 2020. Based on preliminary unaudited information, the Company expects to report roughly $4.5 million in revenue for Q4 of fiscal 2020. This represents a 230 percent increase versus $1.4 million in Q4 of fiscal 2019 and a 62 percent sequential increase from Q3 of fiscal 2020.

Revenue for the month of March was roughly $2.9 million. This represents 65 percent of total revenue for the entire quarter. Revenue generated in the month of March 2020 was 6 percent higher than the total revenue for the entire Q3 of fiscal 2020. For fiscal year 2020, the Company’s revenue increased 218 percent to roughly $14.5 million, versus $4.6 million in fiscal 2019.

AMMO, Inc. (POWW), closed Tuesday's trading session at $1.62, up 6.2992%, on 66,792 volume with 94 trades. The average volume for the last 3 months is 25,526 and the stock's 52-week low/high is $0.959999978/$2.99.

Cypress Development Corp. (CYDVF)

Streetwise Reports, 24hgold, Proactive Investors, Simply Wall St, Investing News, YCharts, Ceo.ca, InvestorsHub, Barchart, HoweStreet.com, TMXmoney, Nasdaq, Morningstar, GlobeNewswire, Mining Feeds, Dividend Investor, Energy and Gold, Newsfilecorp, Junior Mining Network, Seeking Alpha, Canadian Insider, TradingView, Wallet Investor, Resource World, MarketWatch, OTC Markets and Stockhouse reported previously on Cypress Development Corp. (CYDVF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Cypress Development Corp. is an exploration company centered on developing its 100 percent-owned Clayton Valley Lithium Project in the State of Nevada. Exploration and development by the Company has discovered a world-class resource of lithium-bearing claystone next to Albemarle's Silver Peak mine, North America's only lithium brine operation. Incorporated in 1991, Cypress Development has its corporate headquarters in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Cypress engages in the acquisition, development, exploration, and evaluation of mineral properties in the USA and Canada. The Company explores for lithium, silver, and zinc deposits. Its flagship project is the above-mentioned Clayton Valley Lithium Project. The size of the resource makes the Clayton Valley Project a first-class target with the potential to impact the future supply of lithium for the fast-growing worldwide lithium-ion battery market.

Cypress Development owns 100 percent of two claim blocks, Dean and Glory, totalling roughly 5,700 acres. Lithium mineralization occurs within montmorillonite clays throughout the sediments to a depth of a minimum 120 meters. Metallurgical tests have shown the claystone is weak acid leachable with lithium extractions over 80 percent in 2 to 8 hours in agitated leach tests using sulfuric acid. These high extractions indicate the dominant lithium-bearing minerals present are not hectorite, a refractory clay mineral that requires roasting to liberate the lithium.

Recently, Cypress Development reported that the test program at NORAM Engineering and Constructors Ltd. (NORAM) is complete and initial results are positive. As reported in a November 14, 2019 press release, NORAM was contracted to examine the downstream portion of the revised extraction flowsheet for Cypress Development’s Clayton Valley Lithium Project. Testing was conducted at BC Research, Inc., a member of the NORAM Group of companies in Richmond, British Columbia.

Initial results are positive and indicate the target levels of lithium concentration and rejection of impurities in solution were attained. The pending final report will be used to update the mass balance in the process flowsheet and complete the remining step in Cypress Development’s continuing Prefeasibility Study (PFS) on the project.

Cypress Development Corp. (CYDVF), closed Tuesday's trading session at $0.1243, up 1.304%, on 15,480 volume with 3 trades. The average volume for the last 3 months is 48,361 and the stock's 52-week low/high is $0.082400001/$0.185599997.

Goliath Resources Limited (GOTRF)

TradingView, Institutional Gold Research Group, Small Cap Power, Mining News Feed, Market Screener, Global Banking and Finance, Nasdaq, OTC Markets, Sector Newswire, Stockhouse, InvestorX, Mining Stock Education, StreetWise Reports, Simply Wall St, TMX Matrix, Junior Mining Network, InvestorIntel, Wallet Investor, Stockwatch, 321gold.com, GlobeNewswire and Canadian Mining and Energy reported earlier on Goliath Resources Limited (GOTRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Goliath Resources Limited is a project generator of precious metals projects focused in the prolific Golden Triangle and surrounding area of northwestern British Columbia. The Company controls four highly prospective properties. These include Bingo, Golddigger, Lucky Strike and Copperhead encompassing more than 52,000 hectares. Incorporated in 2017, Goliath Resources is based in Toronto, Ontario. The Company lists on the OTC Markets’ OTCQB.

Goliath Resources has four separate option agreements to acquire 100 percent of these four highly prospective properties. These funds are presently reserved for the newly drilled discovery of Au-Ag-Cu-Mo at the Lorne Creek Porphyry System on its Lucky Strike Property and High-Grade Polymetallic Gold Zone at the Sure Bet discovery on its Golddigger Property. All four properties have returned extensive mineralization of high grade Gold, Silver and/or Copper from exposed bedrock in situ at surface.

Goliath Resources reported in October of 2019 the original discovery of high-grade gold and polymetallic mineralization over a wide area on its 100 percent controlled Golddigger Property. The newly discovered area is referred to as the Sure Bet Zone. It measures 1550m by 1130m and remains open in all directions.

Goliath’s Lucky Strike property covers 31,511 hectares. Lucky Strike has logging road access. It is within a few kilometers to a major highway, power, rail and only 40 kilometers north of major infrastructure in Terrace, British Columbia. The Company’s Copperhead property covers 4,354 hectares and it is 6 kilometers to the nearest road and power-line. Copperhead is positioned 35 kilometers southwest of Smithers, British Columbia and positioned south of the Golden Triangle region.

The Company’s Bingo property covers 989 Hectares. This property is only 10 kilometers from the historic Anyox historic mining camp, smelter, and power dam situated in the Golden Triangle. Goliath’s Golddigger property covers 18,587 hectares. It is located on tide water 30 kilometers southeast of Stewart, British Columbia in the Golden Triangle.

In March, Goliath Resources reported channel sample results from the Goldilocks Zone on the Gold Star property, which assayed 7.86 g/t AuEq over 3.75m true width. The channel was taken over a 3.75m wide section to partially test a 10.5m wide outcrop containing wide-ranging veining and alteration. The channel started in 9.01 g/t AuEq and ended in 10.79 g/t AuEq and remains open.

Goliath Resources Limited (GOTRF), closed Tuesday's trading session at $0.0805, even for the day, on 44,045 volume. The average volume for the last 3 months is 4,316 and the stock's 52-week low/high is $0.003899999/$0.127599999.

Safe-T Group Ltd. (SFET)

Stocktwits, BOVNews.com, Webull, Investor Welcome, Market Screener, Wallet Investor, MarketWatch, GlobeNewswire, Nasdaq, OTC Markets, PR Newswire, GuruFocus, MarketBeat, MacroTrends, Street Insider, Dwinnex, TradingView, Stockwatch, Barchart, News Welcome, ChartMill, InvestorsHub, YCharts, Simply Wall St, Investing.com, and Seeking Alpha reported earlier on Safe-T Group Ltd. (SFET), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Safe-T Group Ltd. develops and markets cyber security solutions in Israel, North America, the Asia-Pacific, Africa, Europe, and worldwide. The Company is a provider of Secure Access solutions for on-premise and hybrid cloud environments. It is a provider of Zero Trust Access solutions that mitigate attacks on enterprises' business-critical services and sensitive data, while ensuring uninterrupted business continuity. Established in 2013, Safe-T Group has its corporate headquarters in Herzliya, Israel. The Company lists on the NasdaqGS.

Fundamentally, Safe-T Group empowers organizations to easily and dynamically allow the access of users to private apps, services and networks with maximum business continuity and minimal risk. Safe-T Group’s cloud and on-premises solutions ensure that an organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Zero Trust. This means that no one is trusted by default from inside or outside the network. In addition, verification is required from everyone trying to gain access to resources on the network or in the cloud.

As an additional layer of security, Safe-T Group’s integrated business-grade international proxy solution cloud service enables smooth and efficient traffic flow, interruption-free service, unlimited concurrent connections, instant scaling and simple integration with the Company’s services. Safe-T Group has hundreds of enterprise customers worldwide, including a scalable cloud solution in five continents. It recently acquired NetNut Ltd., a residential IP Proxy company, and CyKick Labs’ UBA technology.

Safe-T Group has a global technology and channel partner network and partnership platform with almost 100 ISPs. It also has OEM (Original Equipment Manufacturer) partnerships in the United States (K2, SecureAuth).

Yesterday, Safe-T Group provided an estimated revenue range for Q1 of 2020. On a preliminary and unaudited basis, the Company expects to report Q1 2020 revenue in the range between $1.05 million to $1.15 million. This represents an increase in the range of 146 percent to 169 percent, respectively, versus $0.427 million in Q1 of 2019.

Today, Safe-T Group announced the pricing of an underwritten public offering with expected total gross proceeds of about $8.4 million before deducting underwriting discounts, commissions and other offering expenses payable by Safe-T Group. The Company intends to use the net proceeds from the offering for working capital, general corporate purposes and pursuing strategic opportunities, including, but not limited to, business combination transactions, and to repay up to $536,086 of the remaining convertible loan from April 2019. The expectation is that the offering will close on April 23rd, 2020, subject to customary closing conditions.

Safe-T Group Ltd. (SFET), closed Tuesday's trading session at $1.10, off by 32.0988%, on 4,326,903 volume. The average volume for the last 3 months is 1,008,161 and the stock's 52-week low/high is $0.931800007/$63.3160018.

eMARINE Global, Inc. (EMRN)

TipRanks, Real Investment Advice, StockPulse, TeleTrader, Wallmine, Market Wire News, TradingView, Street Insider, Wallet Investor, Stockhouse, Market Screener, InvestorsHub, Morningstar, Stockopedia, Nasdaq, GlobeNewswire, Global Banking and Finance, Stockwatch, Simply Wall St, and Financial Buzz reported beforehand on eMARINE Global, Inc. (EMRN), and today we report the Company, here at the QualityStocks Daily Newsletter.

eMARINE Global, Inc. is a top provider of information and communications technology (ICT) for the maritime industry. It provides solutions for the collection, integration and display of maritime information abroad and ashore through electronic means to enhance berth to berth navigation and related services. The Company formerly went by the name Pollex, Inc. It changed its name to eMarine Global, Inc. in August of 2017. Incorporated in 2001, eMARINE Global has offices in Ulsan and Seoul, South Korea.

eMARINE Global’s solutions provide the most efficient means to secure the safety of life at sea and to protect the marine environment. All products and services are offered through subscription, installation, updates and/or maintenance contracts.

eMARINE Global is working with a growing base of marquee customers to reach maritime ICT convergence by way of fully integrated products and services. The Company offers state-of-the-art e-navigation, marine Internet of Things (IoT), and marine big data solutions, primarily in Korea with near-term expansion into U.S. and Chinese markets.

eMARINE Global offers electronic chart display and information systems (ECDIS), a computer-based navigation system; and electronic navigation charts (ENC), which integrates position information from the global positioning system (GPS) and other navigational sensors, including radar, fathometer, and automatic identification systems. eMARINE Global also provides smart ship solutions, including intra-ship integrated gateway (ISIG), an intra-ship network; collision avoidance and optimal voyage systems; and remote maintenance and engine monitoring systems.

The Company engages in the distribution of overseas solutions, such as CARIS, a maritime GIS software; digital charts; and Hatteland, a maritime-specialized hardware. Moreover, it provides Aids to Navigation (AtoN) management systems consisting of maritime weather signals total management system, and e-A2N device.

Recently, eMARINE Global announced it was chosen as the preferred bidder for a large-scale vessel traffic system (VTS) project for the Korean Coast Guard. The Company will work with foremost domestic system integrators, including Daily Blockchain and STX Engine, to complete the VTS project. In addition, the project team will include worldwide surveillance solution providers, including SAAB, an eMARINE partner company, and Terma A/S. The Korean Coast Guard VTS project is budgeted at $14 million over two years.

With the negotiated terms of the contract, the project consortium will construct two VTS operating centers, one in Mokpo and one in Gunsan, both located on the southwest coast of Korea. The project will include three radar systems in Mokpo and two radar systems in Gunsan.

eMARINE Global, Inc. (EMRN), closed Tuesday's trading session at $0.25, up 1,512.90%, on 1,302 volume with 6 trades. The average volume for the last 3 months is 547 and the stock's 52-week low/high is $0.0131/$3.00.

CannaPharmaRX, Inc. (CPMD)

Hottest Stock Picks, Real Investment Advice, Stockaholics, Zacks, Infront Analytics, Capital Cube, Morningstar, Stockhouse, Barchart, The Street, Simply Wall St, GuruFocus, Insider Tracking, Daily Marijuana Observer, Stockopedia, Dividend Investors, The Seed Investor, PR Newswire, Marketwired, Seeking Alpha, InvestorsHub, Wallet Investor, Stockwatch, and 4-Traders reported beforehand on CannaPharmaRX, Inc. (CPMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Irvine, California, CannaPharmaRX, Inc. focuses on the acquisition and development of state-of-the-art cannabis grow facilities located in Canada. The Company’s business strategy is to become a leader in high quality and low-cost production of cannabis in Canada via the development, acquisition and enhancement of existing facilities. CannaPharmaRx’s dedication is to operating high quality facilities employing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis. CannaPharmaRX lists on the OTC Markets.

The Company’s corporate mission is to produce high quality, carbon footprint efficient pharmaceutical grade medical cannabis in ultramodern, highly efficient facilities in Canada for the distribution to wholesale licensed retailers across the nation. CannaPharmaRX’s vision is the immediate national expansion via acquisitions for the continuing development of cannabis production facilities.

Recently, the Company completed an initial acquisition of a 48,500 square foot cannabis grow facility now under development. CannaPharmaRX is presently in discussions with other companies concerning potential acquisitions or business combinations. It is currently targeting acquisitions of companies in the final stages of obtaining cannabis licensee applications or those which are nearing revenue generation.

The Company’s Hanover facility in the Province of Ontario includes 10 acres of land and a 48.8 thousand square foot growing space to produce 9.6 thousand kg of cannabis each year. Construction is underway and the projection is to complete by September of this year. CannaPharmaRX is projected to be licensed to cultivate, granted by Health Canada October 2019, and licensed to sell, granted by Health Canada December 2019; its sales will begin immediately.

This past January, CannaPharmaRX announced it completed the acquisition of Alternative Medical Solutions, Inc., (AMS), a Province of Ontario corporation. With this agreement, Hanover CPMD Acquisition Corp. (HCAC), a wholly-owned subsidiary of CannaPharmaRX, acquired all of the issued and outstanding securities of AMS for total consideration of CAD$12,710,000 comprising cash, common stock, and a promissory note. AMS is a late stage marijuana licensed producer applicant in Canada presently operating in the Pre-License Inspection and Licensing phase, which is Stage 5 of 6, with a fully approved license.

Recently, CannaPharmaRx announced it completed the acquisition of a minority interest in GN Ventures, LTD., (GNC), a Province of Alberta corporation, engaged in the development of Canadian cannabis cultivation facilities. With this stock purchase agreement, the Company acquired roughly 18 percent of the issued and outstanding securities of GNC for total consideration of 7,998,963 shares of CPMD common stock. The Company also acquired warrants exercisable to purchase an additional 2,500,000 shares of GN at an exercise price of CAD$1.00 per share. GNC owns a 60,000 square foot cannabis cultivation and grow facility situated on 38 acres in Stevensville, Ontario.

CannaPharmaRX, Inc. (CPMD), closed Tuesday's trading session at $0.51, up 1,440.79%, on 220 volume with 2 trades. The average volume for the last 3 months is 963 and the stock's 52-week low/high is $0.033100001/$2.99.

The American Energy Group, Ltd. (AEGG)

Penny Stock Tweets, Stockwatch, Dividend Investor, Real Investment Advice, InvestorsHub, Research Gate, Zacks, Stockhouse, 4-Traders, GuruFocus, The Street, MarketWatch, Wallet Investor, Marketbeat, Market Screener, and Business Wire reported beforehand on The American Energy Group, Ltd. (AEGG), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

The American Energy Group, Ltd.  (AEGG)  is an energy resource royalty company listed on the OTC Markets. It is a non-operating oil and gas enterprise. The Company has an 18 percent  gross overriding royalty interest on the producing Yasin Block 2468-7 in South-Central Pakistan that comprises 172 acres. AEGG  has its corporate office  in Westport, Connecticut.

The Company’s strategy is to expand its portfolio of royalty and convertible Working Interests (WIs) in long-term petroleum leases. Additionally, its strategy is to create shareholder value through investing in exploration and early development projects with high cash-flow potential. AEGG’s focus will be high-impact South Asia energy development opportunities that are characterized by manifold target structures and locations with a potential for considerable hydrocarbon reserves.

AEGG’s other core assets comprise royalties and convertible carried WI’s in oil and gas leases. These include a  2.5 percent carried WI in Zamzama North Block No. 2667-8 under exploration  in South-Central, Sindh Province, Pakistan. Heritage Oil and Gas is the operator. This property consists of 557,951 square acres.

In addition, in the Zamzama North and Sanjawi Blocks, AEGG has the option to convert its 2.5 percent  carried WI’s at any time, on a well by well basis to a 1.5 percent  royalty, free of the costs of exploration  and development of the leases.  The convertible carried  WI  is "carried", which means  free of exploration and development costs,  as to the first  three wells for Zamzama North, and the first two wells for Sanjawi.

Furthermore, AEGG has a 2.5 percent carried WI in Sanjawi Block No. 3068-2 under exploration in North-Central, Baluchistan Province, Pakistan. Heritage Oil and Gas is the operator. This property is 302,895 square acres. The other joint venture (JV) partners are Hycarbex-American Energy, Inc, Sprint Energy, and Trakker Energy.

In May of 2018, AEGG announced that the Government of Pakistan granted to the Company's wholly-owned subsidiary, Hycarbex-American Energy an extension to the Yasin Exploration License relating back to the date of the request for extension in March of 2013. Company Management promptly started its plans for exploration and development activities on the Yasin Exploration License based on this extension.

The American Energy Group, Ltd. (AEGG), closed Tuesday's trading session at $0.025, up 104.0816%, on 21,250 volume with 2 trades. The average volume for the last 3 months is 8,780 and the stock's 52-week low/high is $0.005499999/$0.082999996.

DXI Energy, Inc. (DXIEF)

Stockfuse, MarketWatch, InvestorsHub, Zacks, Oilandgas360, Tip Ranks, Wallet Investor, Stock Digest, Amigo Bulls, Dividend Investor, Stockhouse, Private Capital News Wire, Stockwatch, Equity Clock, The Street, Barchart, Marketwired, YCharts, Capital Cube, Street Insider, Marketbeat, ValueForum, and Seeking Alpha reported on DXI Energy, Inc. (DXIEF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

DXI Energy, Inc. is a tactical acquisitor and developer of strategic energy resources. The Company is an upstream oil and gas exploration and production company. DXI Energy operates in Colorado’s Piceance Basin and in the Peace River Arch area in British Columbia  (B.C.). DXI Energy has offices in Calgary, Alberta, and Vancouver, British Columbia. The Company’s shares trade on the OTC Markets’ OTCQB.

In Colorado’s Piceance Basin, DXI Energy has 24,407 net acres.  In the Peace River Arch area in B.C. it has 13,093 net acres. Concerning its project areas, in the Piceance Basin in northwest Colorado, DXI has its Kokopelli project with 12 producing wells with extensive in place infrastructure to supplement future development as product prices dictate. 

The Company’s land holdings in the Piceance Basin highlight potential long-term regional resource value. This is as utilities develop sources of natural gas. For Kokopelli, DXI Energy retains a 25 percent Working Interest (WI) in 2,200 acres (550 net, 2 leases). 

In addition, DXI has its Roan Creek project (West Piceance Hi-Pressure Mancos/Niobrara Gas). This project is 1,960 net acres, 100 percent WI. There is potential development of 8-10 high pressure Mancos/Niobrara 8200’ vertical/Hz wells.

The Woodrush Project in northeastern B.C. encompasses 14,444 net acres (20.701 (gross) with 12 wells (3 oil and gas, 9 natural gas). DXI is the operator and it owns 99 percent of the Project. The Company has a multi-phase plan to expand production and landholdings at the Woodrush Project. It has $13mm invested in production facilities and a related network of pipelines at the Woodrush Project.

Recently, DXI Energy announced that it received all B.C. Oil & Gas Commission (BCOGC) permits to begin the drilling of a key Halfway formation exploration well at its Woodrush NE B.C. complex. Contracts for the building of road access and an environmentally modified drill pad meeting specs of all First Nation stakeholders were issued; construction is underway.

Chief Financial Officer, Mr. David Matheson, said, "With the permit to drill from the BCOGC (inclusive of all other stakeholders), we will now test the voracity of the Paradigm 3D seismic imaging and interpretation software with the drilling and completion of this important Woodrush Halfway pool test prior to winter 2019 break up."

DXI Energy, Inc. (DXIEF), closed Tuesday's trading session at $0.01, up 63.9344%, on 45,882 volume with 8 trades. The average volume for the last 3 months is 61,473 and the stock's 52-week low/high is $0.0023/$0.0383.

Medifocus, Inc. (MDFZF)

MoneyHub, OTC Markets, Wallet Investor, SmallCapVoice, Investor Place, Investor Network, Barchart, Street Insider, Financial Content, Trading View, MarketWatch, and otc.Watch reported beforehand on Medifocus, Inc. (MDFZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medifocus, Inc. has a portfolio of medical technologies that use patented  Focal Thermal Technology  to treat conditions ranging from Prostate Diseases to Breast Cancer. The Company’s portfolio of medical products includes thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer. OTCQB-listed, Medifocus is based in Columbia, Maryland.

The Company owns two technology platforms with approximately 100 issued and pending U.S. and worldwide patents. One platform is the “Endo-thermotherapy Platform”. The other platform is the “Adaptive Phased Array Microwave Focusing Platform”.

Based on these proprietary technology platforms, Medifocus has developed two advanced therapeutic products. One is the Prolieve® system for the treatment of BPH. The other is the Adaptive Phased Array (APA)-1000 system for the treatment of breast cancer.

The Prolieve® Thermodilatation™ System provides symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) via a simple, 45-minute, in-office treatment. Prolieve® is Food and Drug Administration (FDA) and Medicare approved for treating symptomatic BPH with more than 100,000 cases performed in the U.S. alone, and with proven long-term safety, efficacy, and durability. The purpose of the Prolieve system is to provide a relatively painless and effective alternative to drug therapy, and also certain types of surgical procedures to treat the symptoms of BPH.

Medifocus’ Heat Activated Gene Therapy, exclusively licensed from Duke University, aims at using the Company’s Focal Thermal Technology to enhance selective expression of therapeutic genes injected intratumorally to optimize cancer cell killing while lessening systemic side effects.

The APA 1000 Breast Cancer Treatment System developed by the Massachusetts Institute of Technology (MIT) has been shown in Phase 2 clinical trials to offer substantial additional shrinkage of the sizes of breast cancer in combined ChemoThermal therapy versus Chemotherapy alone. Additionally, it was shown to be effective in reducing margin positivity when patients were treated with APA 1000 before lumpectomy.

Recently, Medifocus announced that its Prolieve® Thermodilatation™ procedure for the treatment of BPH have been performed and reimbursed by insurance carriers in Hong Kong.

Dr. William Jow, said, “We are pleased that our efforts, together with the contribution from our Asian partners, are starting to yield tangible financial results from Prolieve® sales. Through our resolution in promoting Prolieve® in Asia and after having presented at three major international conferences within the past 16 months, I would like to see Prolieve® sales start to pick up in the near future both domestically and internationally. We are pleased to enter the fast-growing Asia markets where BPH and cancers of the prostate and breast are quickly becoming major public health concerns.”

Medifocus, Inc. (MDFZF), closed Tuesday's trading session at $0.00303, up 68.3333%, on 4,800 volume with 1 trade. The average volume for the last 3 months is 4,352 and the stock's 52-week low/high is $0.001099999/$0.020099999.

Almost Never Films, Inc. (HLWD)

Street Insider, InvestorsHub, PR Newswire, Ticker Report, Penny Stock Hub, OTC Markets, The Street, YCharts, Barchart, Simply Wall St, Dividend Investor, Street Insider, Market Exclusive, MarketWatch, Marketbeat, and Equity Clock reported beforehand on Almost Never Films, Inc. (HLWD), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Almost Never Films,  Inc. is an independent film company headquartered in Los Angeles, California. The Company’s emphasis is on film production, finance and production related services for movies under budgets of $35 million. Its business is to enable relationships between creative talent and companies who produce, finance and distribute motion pictures. Almost Never Films’ shares trade on the OTC Markets.

Almost Never Films’ goal is to create, acquire, or license rights to materials upon which it believes motion pictures can be based (screenplays, books, short stories, etc.). The Company has a strategic partnership with Pure Flix Entertainment. This partnership is a multi-film financing agreement to produce six faith-based original motion pictures.

Pure Flix Entertainment is a U.S. independent Christian film and television studio, based in Scottsdale, Arizona. Pure Flix Entertainment will distribute the films globally in new media format. Almost Never Films will contribute its financial, development, and production services.

Almost Never Films previously announced the release of its two faith-based films "The Prayer Box" and "Christmas Manger" (formerly named "Bethlehem Ranch") by Universal Pictures Home Entertainment, the home video distribution division of Universal Pictures. The launch of these two films marks the completion of the first two films of a multi-film financing agreement between Almost Never Films and Pure Flix Entertainment.

Recently, Almost Never Films announced that ION Television acquired the Company's holiday feature "Country Christmas Album". The network aired the film during 2018's holiday season. ION Television is a foremost family-oriented entertainment network. ION Television is a top 10-ranked U.S. general entertainment network. It is the flagship of the independent, privately held media company, ION Media. ION Media's 70 full-power stations reach 102 million homes.

The people behind Almost Never Films are originally from the finance industry. The Company is made up of private equity and investment professionals that have a passion for motion pictures.

Almost Never Films, Inc. (HLWD), closed Tuesday's trading session at $0.4999, up 233.2667%, on 350 volume with 2 trades. The average volume for the last 3 months is 174 and the stock's 52-week low/high is $0.150000005/$1.00.

Regen BioPharma, Inc. (RGBP)

Small Cap Solutions, InvestorTrendz, Insider Financial, TopPennyStockMovers, YCharts, ProTrader, Emerging Growth, SmallCapVoice, Wall Street Mover, TheMicrocapNews, and The OTC Reporter reported earlier on Regen BioPharma, Inc. (RGBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Regen BioPharma, Inc. is a biotechnology company listed on the OTC Markets’ OTCQB. The Company works to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. Its aim is to quickly advance these technologies through pre-clinical and Phase I/II clinical trials.  Checkpoint Immunology, Inc. is a wholly-owned subsidiary of the Company. Regen BioPharma has its head office in La Mesa, California.

At present, Regen BioPharma is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer. Furthermore, it is focusing  on developing stem cell treatments for aplastic anemia. Fundamentally, the Company is working to increase the quality of life through therapies involving small molecules, stem cell treatments, and the body's own immune system.  It is currently developing products treating blood disorders employing small molecules and gene silencing (DiffronC) and treating cancer with immunotherapy (dCellVax). 

Regen BioPharma is also modulating vital molecular processes in cancer stem cells by way of its patented molecular targeting approaches (BORIS). In addition, it is repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). 

Regen BioPharma is centering on small molecules to activate and inhibit its main target of interest, NR2F6. The Company is continuing to develop the NR2F6 program in-house before entering into any potential partnerships. It has granted CheckPoint Immunology an exclusive international license to develop and commercialize Regen's NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen BioPharma’s small molecule technology from its other Intellectual Property (IP) to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.

In September, Regen BioPharma reported that its researchers identified a series of small molecule drugs, which inhibit NR2F6 as well as activate human immune cells ex-vivo. Evidence provided by studies suggest that NR2F6 represses the body's immune response against tumors. Therefore, inhibiting NR2F6 may lead to enhanced immune response against cancerous tumor cells.

Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma, said, "Based on the known activities of NR2F6, we expect that inhibiting its activity will lead to increased T cell activation. We found that several of our NR2F6 antagonists can activate human immune cells, such as T cells, leading to increased IL-17a production in a concentration-dependent manner."

Recently, Regen BioPharma reported that its researchers determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). Regen will pursue this testing as a joint venture (JV) with Zander Therapeutics, Inc. Zander Therapeutics has been granted an exclusive license by Regen to develop and commercialize the Company's NR2F6 IP for veterinary applications.

Regen BioPharma, Inc. (RGBP), closed Tuesday's trading session at $0.0002, up 100.00%, on 1,000,000 volume with 1 trade. The average volume for the last 3 months is 4,570,119 and the stock's 52-week low/high is $0.000000999/$0.002899999.

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) was featured today in the 420 with CNW by CannabisNewsWire. The state of Ohio has eased some of its medical marijuana restrictions after repeated complaints that the current system made it difficult for patients to get their medicine when they needed it. The need for a system that works for the patients was further underscored by the danger posed by the Coronavirus pandemic. It forced people to leave the confines of their homes more often than they would have liked, putting them at a greater risk of contracting the virus.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $0.521, up 4.20%, on 5,160 volume with 17 trades. The average volume for the last 3 months is 44,047 and the stock's 52-week low/high is $0.279000014/$4.07000017.

Recent News

InsuraGuest Technologies, Inc. (TSX.V: ISGI)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI).

InsuraGuest Technologies (TSX.V: ISGI) today announced that its wholly owned U.S. subsidiary, InsuraGuest Insurance Agency, LLC (the “Agency”), is now licensed to sell all lines of insurance in 47 out of the 50 U.S. states and Washington, D.C. According to the update, the Agency is registered and licensed to sell accident and health, casualty, life and property insurance in the District of Columbia and all states with exception to Massachusetts, New York and Washington, where it has submitted application and expects to be approved to sell insurance within the next 30 days in these three remaining states. To view the full press release, visit http://nnw.fm/6P0Dk

InsuraGuest Technologies, Inc. (TSX.V: ISGI) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (TSX.V: ISGI), closed Tuesday's trading session at $0.13, up 30.00%, on 37,500 volume with 21 trades. The average volume for the last 3 months is 31,744 and the stock's 52-week low/high is $0.045/$0.34.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

Digital marketing and consumer data management technology innovator SRAX Inc. (NASDAQ: SRAX) is adapting to and overcoming the new challenges of 2020. From new laws regarding data collection and elimination of social gatherings due to stay-at-home orders, SRAX is helping consumers and the brands they trust stay connected. Also today, NetworkNewsWire released a report on the company detailing how SRAX won the inaugural LD Micro March Madness tournament. SRAX was the lowest seed remaining in the competition after it made the “Sweet 16,” and managed to secure the win. The company recently launched its Stock for Ads Program, offering media solutions for stock payments to help businesses connect with their clients and protect cash during this critical time. LD Micro noted that the company’s ability to remain active, transparent, and monetarily responsible during this time will pay big dividends in the future. SRAX has paid to attend LD Mirco events in years past and is a proud sponsor of LD Micro.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $1.86, off by 5.102%, on 13,392 volume with 98 trades. The average volume for the last 3 months is 52,985 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Reliance on foreign and malign sources for critical materials is a national security risk. Though the United States is by far the largest consumer of uranium in the world, the country imports nearly 100% its uranium, much from state-owned foreign sources, strangling domestic suppliers and creating a hazardous situation for the U.S. supply chain and electrical grid. Many Americans may well know of the country’s near-100% dependence on China for critical rare earth elements. However, most may not realize that America is also nearly 100% dependent on uranium imports—increasingly imported from entities owned by the governments of Russia, China and their allies. Like rare earth elements, uranium is designated by the U.S. government as critical to the nation’s security and economic prosperity, and the Department of Interior warned, “This dependency of the United States on foreign sources [of uranium] creates a strategic vulnerability for both its economy and military to adverse foreign government action, natural disaster, and other events that can disrupt supply of these key minerals.” Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) (UUUU Profile), the United States’ leading domestic producer of uranium, has led the charge in efforts to warn the U.S. government about the security threats to uranium supply chain disruption, and also recently announced that it is working to help bring rare earth processing back to the U.S. by leveraging its White Mesa Mill. If the U.S. fails to act, 20% of the nation’s electricity — and 55% of its clean, carbon-free electricity — may become hostage to malign foreign sources of uranium, and recent events show that any supply chain disruption, malicious or well-intentioned, can have a devastating impact. 

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

 

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $1.56, off by 7.1429%, on 1,898,838 volume with 4,499 trades. The average volume for the last 3 months is 1,491,609 and the stock's 52-week low/high is $0.779999971/$3.31999993.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying its cutting-edge technology to cancer research, released its financial report for fiscal year 2019, ending December 31, 2019. The report also identified fourth-quarter highlights for the company (http://nnw.fm/5uhu6).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $1.43, off by 4.0268%, on 412,644 volume with 1,236 trades. The average volume for the last 3 months is 560,212 and the stock's 52-week low/high is $1.25/$8.50.

Recent News

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA)

The QualityStocks Daily Newsletter would like to spotlight PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA).

Car dealership culture is evolving as the new coronavirus ushers in social distancing. As the future of auto sales seems to be online, companies such as PowerBand Solutions Inc. (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) are uniquely positioned to benefit and contribute to the creation of a viable, exclusively online auto trading marketplace.

A Better Way to Connect and Acquire Vehicles

PowerBand’s mission is to create an online, consumer-directed marketplace that streamlines the interactions among all participants in the automotive industry. It transforms today’s antiquated business model with speed, transparency, access to information and ease of use for consumers and dealers.

Consumers can easily connect with new sources to buy vehicles, network with motivated buyers and sellers, maximize their trade-in values, improve their customer experience. PowerBand’s standardized system and transaction process also increase efficiencies and benefits with hands-on, process-driven, in-store training and support.

Through internal development, acquisitions, joint ventures and strategic partnerships, PowerBand is developing solutions for consumers, dealers, manufacturers, commercial customers and lenders that are poised to transform the trillion-dollar U.S. automotive industry.

The PowerBand Auto Platform

PowerBand’s transaction platform was developed by a team of experienced automotive, technology and finance experts, and has been refined through years of operational experience. Built on the core belief that the consumer prefers to primarily conduct automotive transactions online and avoid interactions with unnecessary middlemen, PowerBand’s product solutions include:

  • Leasing: PowerBand is currently licensed in 33 U.S. states via a majority interest in MUSA Auto Finance LLC, an advanced online leasing technology platform that has transformed the new and used vehicle leasing industry. A partnership with Tesla was recently finalized, making MUSA the only approved, non-captive lease partner for Tesla in the U.S.
  • Inventory and Financing: A partnership with RouteOne LLC, a leading financial platform founded in 2002 by Ally Financial, Ford Motor Credit Co., TD Auto Finance and Toyota Financial Services, allows access to a network of more than 18,000 dealerships and 1,400 financing sources.
  • Auction Platform: PowerBand and its joint-venture partner, D2D Auto Auctions, are developing a direct consumer-to-dealer and a consumer-to-consumer automotive portal, which will provide an innovative alternative to physical dealership and auction locations.
  • LiveNet Auction: An online platform portal that allows dealers to create instant live vehicle auctions to a vast network of the industry’s top used vehicle buyers.
  • MarketPlace Auction: An online listing auction site for buying and selling automotive inventory – ideal for dealers, fleet, OEM and rental companies.
  • Used Vehicle Inspections: An LOI agreement with TÜV NORD Mobility Inc., a German-based global leader in vehicle inspections operating in more than 70 countries, will provide the most comprehensive, certified vehicle inspection reports available in North America. Appointments booked within the platform can be performed nearly anywhere.
  • Product Development: PowerBand’s comprehensive consumer solution, Driveaway, will be a fully transactional consumer marketplace where dealers and consumers can buy, sell, trade-in and finance vehicles, often in seconds, from the comfort of their home.

Automotive’s Growing Markets

The automotive dealership and commercial fleet vehicle auction industry is a $100-billion sector with more than 40 million used vehicles transacted in the U.S. each year. Of those, ten million are sold through auctions. From 2013 to 2017, the growth of online-only auctions far outpaced physical auctions, growing at a 33% compound annual growth rate compared to 2% CAGR at physical auctions.

Automotive leasing is another large, growing and fragmented market, generating approximately $120-billion in annual revenue. As a percentage of vehicle sales, leasing reached 30% in 2018, up from 21% in 2012, and is seen as a substantial opportunity for PowerBand and MUSA Auto Finance. Using proprietary technology and by focusing on high-quality, credit-worthy customers, MUSA grew its automotive lease originations to $182 million.

Disrupting Auto Leasing with MUSA

Legacy solutions are complicated, expensive and slow at processing leases. MUSA’s first-of-its-kind technology platform eliminates third-party decisions and the human capital required in the underwriting process. MUSA’s platform navigates the entire customer experience – underwriting, funding and the delivery process – within minutes. Leases can be approved in seconds.

PowerBand’s acquisition of MUSA brings together two leading-edge companies with the vision to become a one-stop platform for the entire vehicle purchase lifecycle.

Experienced Leadership

PowerBand is led by a collection of automotive veterans with a passion to collectively and positively impact the industry.

  • Kelly Jennings, president and CEO, is the founder of PowerBand Solutions and a franchise dealer owner/operator with more than 27 years of automotive experience. Jennings received General Motor’s Triple Crown Award, Ford Motor Company President’s Award and Honda Canada’s Excellence Award.
  • Darrin Swenson, COO of PowerBand and D2D Auto Auctions/Hunt Automotive Group, has more than 25 years of automotive/auction experience.
  • Jeff Morgan, CEO MUSA, holds over 25 years of experience in the auto finance sector.

 

PowerBand Solutions Inc. (OTCQB: PWWBF), closed Tuesday's trading session at $0.10, off by 8.4249%, on 57,600 volume with 2 trades. The average volume for the last 3 months is 37,894 and the stock's 52-week low/high is $0.038600001/$0.230000004.

Recent News

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, commercial hemp enterprise and multi-channel lifestyle company, today announced that its wholly-owned subsidiaries, CLR Roasters LLC and Khrysos Industries, Inc. (the "US Partners") have entered into an agreement with H&H Coffee Group Export Corp and The Nica Hemp Cooperative, Inc (the "Nicaragua Partners") to acquire the 2,200 acre Chaguitillo Farms in Sebaco-Matagalpa, Nicaragua. To view the full press release, visit http://cnw.fm/KJiE9

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Tuesday's trading session at $1.68, up 1.2048%, on 365,798 volume with 1,788 trades. The average volume for the last 3 months is 852,876 and the stock's 52-week low/high is $0.610000014/$6.76999998.

Recent News

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has filed an important new patent application in the United States describing the use of its DehydraTECH(TM) technology for the delivery of antiviral drugs. According to the update, the technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS. To view the full press release, visit http://cnw.fm/9fGWH

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Tuesday's trading session at $0.3293, up 7.4038%, on 60,004 volume with 61 trades. The average volume for the last 3 months is 100,647 and the stock's 52-week low/high is $0.229499995/$1.13999998.

Recent News

Cannabis Global, Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Global, Inc. (MCTC).

Cannabis Global (OTC: MCTC), a cannabinoid and hemp extract science forward company developing infusion and delivery technologies, today announced a new line of cannabinoid beverage infusion technologies and the industry's first Tetrahydrocannabivarin (“THC-V”) tea and coffee products. According to the update, the Company plans to begin marketing both the infusion technologies and the tea and coffee products beginning May 1, 2020. To view the full press release, visit http://cnw.fm/QtXr4

Cannabis Global, Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

Cannabis Global, Inc. (MCTC), closed Tuesday's trading session at $0.21, up 10.5263%, on 33,395 volume with 22 trades. The average volume for the last 3 months is 8,334 and the stock's 52-week low/high is $0.05/$3.00.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. According to the update, Inman will lead in defining clinical developmental strategies, clinical protocol design, study conduct, and managing risk assessment in this new position. To view the full press release, visit http://nnw.fm/Q0xrJ

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $1.99, off by 2.451%, on 1,015,099 volume with 3,624 trades. The average volume for the last 3 months is 8,002,955 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

OriginClear (OTC: OCLN)

The QualityStocks Daily Newsletter would like to spotlight OriginClear (OTC: OCLN).

OriginClear (OTCQB: OCLN), a leading provider of water treatment solutions, today announced that it has relocated its corporate headquarters from Los Angeles to combine with its manufacturing site in McKinney, near Dallas, Texas. “We have enjoyed our stay at the La Kretz Campus of the Los Angeles Cleantech Incubator complex, including its extraordinary prototyping resources and its dedicated team,” OriginClear CEO Riggs Eckelberry said in the news release. To view the full press release, visit http://nnw.fm/hm3IG

OriginClear (OTC: OCLN) leads the self-reliant water revolution, deploying advanced technologies at the point of use, with modular, prefabricated systems that create durable assets and water independence for industry, commerce and agriculture.

Failing infrastructure and the rising cost of water are driving businesses to treat their own water. OriginClear leads this megatrend with on-premise systems enabling very high purification and recycling levels that centralized systems cannot achieve.

Systems installed at the point of use become productive assets for businesses that also increase property values. And OriginClear helps corporations improve their environmental, social and governance (ESG) standings with world-class water management.

Operations & Markets

OriginClear leads a new generation of water companies that focus on meeting the needs of businesses looking for compact, advanced technologies that can be shipped to and installed at the point of use. The company manufactures and distributes its professional-grade water treatment and conveyance products to commercial and industrial properties, fielding both direct and indirect sales channels to reach end-market clients such as hotels and resorts, real estate housing developments, office buildings, military installations, schools, farms, food and beverage manufacturers, industrial warehouse, oil and gas producers, and medical and pharmaceutical facilities.

From its Texas-based factory, OriginClear designs and prefabricates an entire line of plug-n-play containerized units called Modular Water Systems™ that enable water purification, recycling and wastewater management.


Industrial Pretreatment Waste Water Treatment Plant (WWTP) designed by Daniel M. Early, using reinforced thermoplastic modules.

These onsite modular products provide clients with water independence through ownership and operational control over water quality, enabling them to increase productivity while reducing environmental, health and safety risks from pollution, contamination and corrosion. Modular water products are trusted to balance performance with cost-effectiveness, enabling business users to go well beyond municipal standards for water quality, therefore achieving high levels of satisfaction for their own customers, and improved sustainability for their properties.

OriginClear’s water treatment equipment can boost real estate asset value as a fundamental capital improvement, combined with long-lasting water savings for the corporate bottom line.

Product Portfolio

OriginClear groups its products into three main categories:

  1. Water Treatment: achieving high grade purification.
  2. Water Conveyance: water transportation and pumping.
  3. Advanced Technologies: commercialization of innovative technologies.

OriginClear’s complete line of compact, on-site, point-of-use products include: advanced purification systems that are skid, rack-mounted and containerized for reverse osmosis, ultrafiltration, media filtration, disinfection, water softening, ion exchange and electrodeionization (EDI), combined as needed in small to medium commercial and industrial applications, and custom-build projects. Water conveyance products include pump and lifting stations, modular storage tanks, and control monitoring panels.

OriginClear’s line of modular water products and systems is key to the self-reliant water treatment revolution as they create “instant infrastructure” – fully engineered, prefabricated and prepackaged systems that use durable, sophisticated materials. The units are available in standard capacities for onsite closed-loop systems at commercial business locations.

The company’s rugged wastewater treatment plants, highly reliable pump stations, and premium water purification units typically offer 25 percent lower initial costs over conventional systems, with greater quality and full connectivity. These pump stations and wastewater treatment products utilize high density thermo-plastics (HDPE) and proprietary, innovative prefabrication methods and materials that deliver the longest life and strongest products.

Breakthrough Technologies

OriginClear has a long history of innovation through its OriginClear Technologies division, which is responsible for identifying leading-edge technologies to solve today’s toughest challenges. These advanced technologies are the centerpiece of the division’s international licensee network. The technologies are developed in OriginClear Technologies, and licensees integrate them into their own products.

Electro Water Separation™ (EWS) and Advanced Oxidation (AOx™) are the principal, well-proven technologies.

EWS is OriginClear’s breakthrough water cleanup technology which utilizes a catalytic process to concentrate and eliminate suspended solids in the worst commercial and industrial wastewater.

AOx is OriginClear’s proprietary advanced oxidation technology which generates a dense cloud of ozone, hydrogen peroxide and hydroxyl radicals, dramatically reducing or eliminating dissolved organic microtoxins, including bacteria and viruses, hormones, drugs, pesticides such as Roundup, and synthetics. AOx has also been shown to effectively reduce harmful chemicals such as ammonia and hydrogen sulfide – the “rotten egg” smell in crude oil that reduces its value.

Through international licensing and partnerships, OriginClear’s advanced technologies are being adopted to treat tough water problems in East and South Asia, Europe and the Middle East, and North America.

Market Opportunity

In just 10 years, the global water services market has doubled into a trillion-dollar industry, driven by improper sanitation and water scarcity. Only 20 percent of all sewage and only 30 percent of all industrial waste are ever treated. Additionally, water leakage results in the loss of 35 percent of all clean water across the planet; reducing that percentage by half would provide clean water for 100 million people. This is a situation of great danger, but also great potential.

The statistics demonstrate that we can no longer rely on the efficiencies of giant, centralized water utilities to meet these challenges. An increasing number of businesses are starting to take notice, instead conducting their own water treatment and recycling. Whether by choice or out of necessity, those businesses that do invest in onsite water systems get a tangible asset on their business and real estate, and can enjoy better water quality at a lower cost.

Out of the public’s eye and with OriginClear’s help, a growing number of self-reliant businesses are building Decentralized Water Wealth™ for themselves while also helping their community. They know that environmental, social and governance (ESG) investing guidelines, which represent $22 trillion of assets under management around the world, specifically note the key indicator of how well corporations manage their water.


10,000 Gallon per Day Industrial Membrane Bioreactor Waste Water Treatment Plant designed by Daniel M. Early, PE, using long-lived Structural Reinforced ThermoPlastic (SRTP)

OriginClear is a key enabler of ESG water management for corporations that are increasingly responsible for what was once delegated to central utilities. For example, when a corporation manages its own water, and uses OriginClear’s proprietary hybrid treatment methods, it can significantly reduce both water use and nutrient footprints (carbon, nitrogen, and phosphorus) in one compact package.

These hybrid processes feature advanced blackwater treatment with advanced clean water processing. They can convert toxic nutrients to less harmful compounds, and even capture them for beneficial reuse purposes, as shown in OriginClear’s recent case study.

Revenue Growth through Synergy

Since OriginClear acquired it in 2015, Progressive Water Treatment has generated steady revenues in the range of a million dollars a quarter. It is now the Fabrication and Manufacturing Division for the whole company. The team at Modular Water Systems, headed by Chief Engineer Daniel M. Early, is responsible for overall design and high-level engineering. It relies on the Fabrication and Manufacturing Division to add incremental revenue for its modular product line, without requiring large increases in personnel.

OriginClear believes that these two business units can develop growing revenues through synergy and ultimately help achieve overall profitability. OriginClear also seeks to acquire profitable water companies that can complement the synergy of its existing units and accelerate both revenues and profitability. However, acquisitions are neither guaranteed, nor essential to OriginClear’s continued growth.

 

Leadership

OriginClear’s management team brings strong leadership and a background in managing business operations, sales, technologies, and finance. The team combines idealism with solid commercial skills, achieving a triple bottom line of environmental, social and financial gain.

Riggs Eckelberry – Chairman, CEO and Co-founder
Riggs Eckelberry is a veteran technology manager who led companies to multiple exits during the high-tech boom of the 90s and early 2000s. Eckelberry came to the water industry from a quarter century in high technology, specializing in commercializing breakthrough technologies. During the dotcom boom, he worked on a series of tech successes, such as Quarterdeck’s CleanSweep; security software vendor Panda Software; and the sale of companies to EarthWeb, BeFree, and BellSouth. Just prior to founding what is now OriginClear, he helped drive security software company CyberDefender to an IPO on the Nasdaq as its president and chief operating officer.

Thomas Marchesello – Chief Operating Officer
Thomas Marchesello is a business operations and technology executive with over 20 years’ experience in manufacturing and distribution of products and services. He has 12 years in private equity M&A, doing buyside acquisitions of small to midsize corporations. He has over 10 years advising innovative corporations on ESG strategy and speaks often about industry trends. He began his career in the U.S. Air Force, Space Command Headquarters for environmental sciences. He has held key roles for Fortune 500 companies such as Sony, Thompson Reuters, Morgan Stanley, and Chicago Mercantile Exchange.

Daniel M. Early, PE – Senior Engineer
For the past 25 years, Dan Early has worked as an engineered products development specialist with very strong understanding of the complex and interconnected disciplines, economies, and governmental regulation needed to develop and sustain modern civil infrastructure systems that reflect a balance of environmental stewardship, social expectations, and cultural requirements. Since 2010, Early has specialized in the research, development, and deployment of next generation water infrastructure technologies using heavy plastic manufacturing. His initiatives and innovations anchor Modular Water Systems’ product line.

Marc Stevens – Director of Fabrication and Manufacturing
Marc Stevens brings nearly 40 years of experience to OriginClear’s manufacturing team. His experience in mechanical design, equipment fabrication, installation and a wide range of projects led to his founding what is now OriginClear’s Fabrication and Manufacturing Division. He supervises the design, building and installation of customized, large-scale water treatment systems, including purification technologies for process waters for boilers and cooling towers, drinking water and various industrial waste water applications. Stevens leads the team that also manufactures OriginClear’s standardized Modular Water Systems.

OriginClear (OCLN), closed Tuesday's trading session at $0.07, off by 6.6667%, on 109,423 volume with 24 trades. The average volume for the last 3 months is 62,533 and the stock's 52-week low/high is $0.05/$2.20000004.

Recent News

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Bolt Metals Corp. (OTCQB: PCRCF).

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade battery metals deposits within the Asia-Pacific region, employing a vertically integrated “minerals-to-market” strategy to leverage these assets to their fullest.

Bolt Metals Corp. is advancing its flagship, 100% controlled Cyclops Nickel-Cobalt located in Papua Province, Indonesia with a mandate to become a key contributor to Asia-Pacific’s rapidly expanding electric vehicle and battery supply chain.

The Cyclops project, uniquely positioned within the world’s largest producer of nickel and in proximity to China, the world’s largest “Gigafactory”, features near surface, strong nickel-cobalt mineralization. The property is situated in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Bolt Metals well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to nickel-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Indonesia has recently approved environmental impact studies for factories to produce battery-grade nickel chemicals in Morowali. The approval will allow investors, such as China’s stainless steel giant Tsingshan Group, to continue the construction of their high-pressure acid leaching plants in Morowali, Central Sulawesi.

Ranjeet Sundher, chief executive officer of Bolt Metals, said: “Indonesia continues to make significant strategic decisions, and this latest announcement represents an important step in Bolt Metals’s efforts to benefit from Indonesia’s rapid development as a leading market for all stages of the EV supply chain. With offices in Vancouver, Shanghai and Jakarta, Bolt Metals is well positioned to leverage Asia’s global dominance in the battery manufacturing sector.”

Indonesia’s commitment extends to the very top of government, with Joko Widodo – Indonesia’s President – stating in September 2019 that “for nickel, we want raw materials to be processed in Indonesia. We want added values”. This supports previous pronouncements from key officials, including Indonesian Maritime Minister, Luhut Pandjaitan who remarked that Indonesia will “become the main player in lithium batteries” and that it will “control the world market”.

The country, which is the world’s top nickel ore exporter, has stopped export of unprocessed nickel ore to support this plan.

During 2019 the Company carried out an extensive exploration and development program on Cyclops and achieved successful nickel results with its drilling and bench-scale scoping tests for processing of materials.

Drilling identified significant horizons of nickel mineralization and bench-scale scoping tests returned positive results for processing of this nickel rich material.

The recovery percentages form the bench-scale test program are set out below (for further information, please refer to the Company’s press release of October 28, 2019):

Sample Nickel (%) Cobalt (%) Iron (%)
Limonite 99.26 98.82 97.77
Low Iron Transition 99.75 97.03 99.22
Saprolite 99.77 >99.9 99.74

 

Selected elevated nickel drill results are provided below from the Company’s shallow drilling program (for further information, please refer to the Company’s press releases of March 5, April 1, April 23, June 13, June 20 and September 10, 2019):

Intersection length (metres from surface) Nickel (%) Cobalt (%)
7.0 2.15% 0.03%
4.0 1.96% 0.04%
2.0 2.00% 0.01%
2.0 1.91% 0.05%

 

2020 will see continued and consistent development in Pacific Rim Cobalt’s strategy as the company continues to set ambitious milestones with the goal of becoming a leading international player in the EV battery metal sector and creating significant long-term shareholder value.

This includes preparations to commission and operate the company’s pilot plant in Canada, which will contain an integrated circuit to produce high-purity nickel and cobalt strip solutions to develop battery-grade nickel and cobalt.

The results of the pilot plant will then be used to establish the design criteria for the subsequent demonstration plant in Indonesia, which will produce nickel and cobalt products suitable to meet market specifications. As well as demonstrating Pacific Rim Cobalt’s ability to produce a product within market specifications, this will also be used to establish the design criteria for the company’s commercial-scale plant.

Pacific Rim Cobalt’s world-class management team includes Ranjeet Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Bolt Metals Corp. (OTCQB: PCRCF), closed Tuesday's trading session at $0.1354, up 12.8333%, on 2,619 volume with 8 trades. The average volume for the last 3 months is 49,441 and the stock's 52-week low/high is $0.079999998/$0.355599999.

Recent News

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)

The QualityStocks Daily Newsletter would like to spotlight Exro Technologies Inc. (OTCQB: EXROF).

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian technology company, is an innovative pioneer in the energy sector. Exro has developed and commercialized an electric power module (EPM) that integrates into existing motor systems to make them smarter. Exro’s patented technology optimizes existing motor performance by automatically sensing and adapting operating parameters to an optimized state, creating measurable efficiency gains, reduced mechanical components and increased system availability.

Applications

Exro’s technology and efficiency optimization algorithms improve the performance and efficiency of electric motors by manipulating power delivery to individual coils, thereby enabling the ability to expand operating parameters. This novel approach is scalable and can be utilized in most variable torque applications.

The widespread applications of Exro’s technology apply to optimizing the performance of electric vehicles, locomotive traction applications, industrial motors, and other variable torque applications that benefit from smart energy conversion.

Intellectual Property

Exro’s proprietary, patented software controls electric motor coils through individual coil switching. This introduction of intelligence into energy conversion at the level of individual coils results in expanded speed/torque capability, improved machine efficiency, reliability, safety and maintenance across a wider operating range. Exro’s advanced control algorithms create smart, real-time optimized power management.

Exro currently holds 15 patents, with 8 patents pending and additional patents under development. The company continues to expand its IP portfolio to support its goal of becoming a globally recognized leader in leveraging advanced control algorithms to improve the performance, efficiency and longevity of electric motors and generators.

Market Opportunity

Electric motors are the single biggest consumer of electricity. They account for about two-thirds of industrial power consumption and about 45% of global power consumption, according to an analysis by the International Energy Agency. Exro’s technology seeks to give industries a new way to look at energy—from electric vehicles, to industrial equipment, to renewable applications like wind farms; we are improving the way energy is consumed.

Laboratory Expansion

The 6,500-square-foot Exro Innovation Center (EIC), scheduled to open spring of 2020 in Calgary, will transition the current Victoria lab into one Calgary based center. The company’s new laboratory space will expand its service capabilities to customers, provide larger test capabilities, and showcase how Exro’s technology can be applied to dramatically improve the performance of electrical motors.

The EIC will also host collaborative events to explore advances in energy consumption and electric motor innovations, with participants from across Canada and around the world.

Strategic Partnerships

  • A strategic agreement with Finland’s Aurora Powertrains Oy, which in 2019 released an all-electric production snowmobile called the “eSled,” will see Exro’s technology added to the Aurora electric powertrain. The snowmobile sector’s economic footprint is estimated at $26 billion in the U.S., $8 billion in Canada, and $5 billion in Europe and Asia.
  • An agreement with Potencia in Mexico serving the last mile vehicle segment will integrate Exro’s custom drive and EPM module into small passenger commercial vehicles (taxis) and fleet delivery trucks
  • A licensing agreement with Motorino Electric, a leader in the Canadian electric transportation industry, will integrate Exro’s Electric Power Module technology into Motorino’s CTi electric bicycle.

Management

Chief Executive Officer Sue Ozdemir is a proven leader in the innovation and manufacturing of electric motors. She has nine years of accomplishments at General Electric, acting as CCO and the CEO of GE’s Small Industrial Motors Division, overseeing the division’s North American and international markets – ultimately building the division into a $160 million enterprise.

Chief Commercial Officer Josh Sobil is leading the seamless adoption of Exro’s growing product portfolio focused on the mobility segment and opening doors in all segments including agriculture, heavy industry, energy, construction, among others.

Executive Chairman Mark Godsy is a serial technology entrepreneur who has been involved in many top tier ventures, including two of Canada’s most successful biotech companies.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), closed Tuesday's trading session at $0.228, up 5.8987%, on 62,891 volume with 26 trades. The average volume for the last 3 months is 104,827 and the stock's 52-week low/high is $0.124389998/$0.522899985.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.23, up 6.1905%, on 4,126 volume with 15 trades. The average volume for the last 3 months is 14,609 and the stock's 52-week low/high is $0.600600004/$3.8499999.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.